CRBP Company Profile and Key Details
NASDAQ : CRBP
Corbus Pharmaceuticals
$8.35
-0.22-2.57%
At Close 4:00 PM59.98
BESG ScoreESG Rating
Price Chart
Stock Price Today
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock declined over -2.57%, trading at $8.35 on NASDAQ, down from the previous close of $8.57. The stock opened at $8.29, fluctuating between $8.10 and $8.57 in the recent session.
Stock Snapshot
8.57
Prev. Close
104.67M
Market Cap
8.1
Day Low
-1.52
P/E Ratio
-5.49
EPS (TTM)
-8.16
Cash Flow per Share
8.29
Open
12.54M
Number of Shares
8.57
Day High
87.41%
Free Float in %
-1.56
Book Value
178.68K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 02, 2026 | 8.48 | 8.57 | 8.10 | 8.35 | 178.68K |
| Feb 27, 2026 | 8.12 | 8.72 | 8.04 | 8.57 | 307.52K |
| Feb 26, 2026 | 7.86 | 8.26 | 7.52 | 8.25 | 443.83K |
| Feb 25, 2026 | 7.64 | 7.87 | 7.53 | 7.77 | 161.3K |
| Feb 24, 2026 | 7.44 | 7.88 | 7.44 | 7.63 | 87.16K |
| Feb 23, 2026 | 7.42 | 7.52 | 7.26 | 7.42 | 82.44K |
| Feb 20, 2026 | 7.56 | 7.67 | 7.23 | 7.42 | 101.66K |
| Feb 19, 2026 | 7.41 | 7.72 | 7.20 | 7.68 | 177.64K |
| Feb 18, 2026 | 7.43 | 7.60 | 7.32 | 7.41 | 113.69K |
| Feb 17, 2026 | 7.54 | 7.61 | 7.24 | 7.52 | 100.36K |
| Feb 13, 2026 | 7.84 | 7.97 | 7.56 | 7.56 | 93.98K |
| Feb 12, 2026 | 7.64 | 7.90 | 7.26 | 7.83 | 158.79K |
| Feb 11, 2026 | 7.93 | 8.08 | 7.38 | 7.62 | 126.74K |
| Feb 10, 2026 | 7.98 | 8.23 | 7.85 | 7.92 | 140.39K |
| Feb 09, 2026 | 7.86 | 8.13 | 7.50 | 7.92 | 153.8K |
| Feb 06, 2026 | 7.53 | 7.89 | 7.41 | 7.83 | 195.66K |
| Feb 05, 2026 | 7.98 | 7.99 | 7.33 | 7.39 | 222.06K |
| Feb 04, 2026 | 8.10 | 8.33 | 7.75 | 8.01 | 110.68K |
| Feb 03, 2026 | 8.34 | 8.39 | 8.01 | 8.10 | 102.54K |
| Feb 02, 2026 | 8.22 | 8.49 | 8.11 | 8.28 | 155.38K |
Contact Details
About Company
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor � (TGF�); and CRB-602, an anti-av�6/av�8 mAb that blocks the activation of TGF� for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Company Information
| Employees | 28 |
| Beta | 2.85 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
9.14+1.17%
Regeneron Pharmaceuticals, Inc.$790.81ARGX-10.16-1.32%
argenx SE$756.76UTHR9.92+1.97%
United Therapeutics Corporation$513.82VRTX-10.8-2.17%
Vertex Pharmaceuticals Incorporated$486.03MDGL3.62+0.84%
Madrigal Pharmaceuticals, Inc.$435.62PRAX-6.16-1.83%
Praxis Precision Medicines, Inc.$330.59KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-7.85-2.36%
Alnylam Pharmaceuticals, Inc.$325.07KRYS-16.83-6.11%
Krystal Biotech, Inc.$258.81ASND8.59+3.68%
Ascendis Pharma A/S$242.09Company Overview
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed at $8.35 USD, losing -$0.22 (-2.57%) from the previous close of $8.57. The stock is currently mid-range between its 52-week high and low $4.64 and $20.56. With a market capitalization of about $104.67 million, Corbus Pharmaceuticals Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.85). Key stats such as the average daily volume over the past year has been around 278.46 thousand shares, volume is running light vs its 52-week average. Headquartered in Norwood, MA, Corbus Pharmaceuticals Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yuval Cohen, the company employs approximately 28 people and listed since October 27, 2014. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.
Technical Performance
CRBP has shown mixed momentum, gaining 7.51% over the past week and -55.54% over the past quarter, though year-to-date performance is up 5.53%. Short-term trend indicators are bullishly aligned (SMA20 5.46%, SMA50 0.97%, SMA200 -16.59%). The stock’s 14-day RSI is 54.22 (neutral), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.87% below its high and over 77.8% above its low. Average 10-day trading volume of 194.66 thousand shares is below the 3-month average of 274.06 thousand, indicating normal recent market interest.
Dividend & Fair Value
Corbus Pharmaceuticals Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.28. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Corbus Pharmaceuticals Holdings, Inc. generated EPS of -$5.51 over the past year. Five-year average earnings growth is 35.71%. Wall Street analysts project EPS growth of -12.92% annually over the next five years. The latest quarter delivered EPS of -$1.90. The next quarter is forecast at -$1.52. Next year's EPS is expected at $40.09. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $53.00 to $38.00. The high target offers 534.73% upside. The low target suggests 355.09% downside. The mean target is $46.71. This offers 459.4% upside. Corbus Pharmaceuticals Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 5.37%. The prior quarter beat by -7.1%. Over the last six quarters, Apple has recorded several small beats. These include -22.41% in August 06, 2024.
Shareholding & Insider Activity
Corbus Pharmaceuticals Holdings, Inc. has 12.26 million shares outstanding. The public float is 7.54 million shares, elevated short interest at 11.80% of float. This equals 1.16 million shares. The short ratio is 11.56 days. Institutional investors hold 82.49% of the float. Insiders own 0.7%. Cormorant Asset Management, LP holds 2.34 million shares, White Barbara has 206.22 thousand shares and Cohen Yuval has 174.32 thousand shares. Over the past six months, insider transactions show net selling. They sold 96.82 thousand shares across 10 transactions.
Frequently Asked Questions
What is the current Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock price?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) stock price is $8.35 in the last trading session. During the trading session, CRBP stock reached the peak price of $8.57 while $8.10 was the lowest point it dropped to. The percentage change in CRBP stock occurred in the recent session was -2.57% while the dollar amount for the price change in CRBP stock was - $0.22.
CRBP's industry and sector of operation?
The NASDAQ listed CRBP is part of Biotechnology industry that operates in the broader Healthcare sector. Corbus Pharmaceuticals Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of CRBP?
Ms. Christina Bertsch
Head of HR
Dr. Rachael Brake Ph.D.
Chief Scientific Officer
Scott Constantine
Senior Director & Head of Clinical Operations
Dr. Yuval Cohen Ph.D.
Chief Executive Officer & Director
Ms. Lindsey Smith
Head of Corporation Communications & Patient Advocacy
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA
Chief Financial Officer
Ted Jenkins
Vice President & Head of Investor Relations
Head of HR
Dr. Rachael Brake Ph.D.
Chief Scientific Officer
Scott Constantine
Senior Director & Head of Clinical Operations
Dr. Yuval Cohen Ph.D.
Chief Executive Officer & Director
Ms. Lindsey Smith
Head of Corporation Communications & Patient Advocacy
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA
Chief Financial Officer
Ted Jenkins
Vice President & Head of Investor Relations
How CRBP did perform over past 52-week?
CRBP's closing price is 79.96% higher than its 52-week low of $4.64 where as its distance from 52-week high of $20.56 is -59.39%.
How many employees does CRBP have?
Number of CRBP employees currently stands at 28.
Link for CRBP official website?
Official Website of CRBP is: https://www.corbuspharma.com
How do I contact CRBP?
CRBP could be contacted at phone 617 963 0100 and can also be accessed through its website. CRBP operates from 500 River Ridge Drive, Norwood, MA 02062, United States.
How many shares of CRBP are traded daily?
CRBP stock volume for the day was 178.68K shares. The average number of CRBP shares traded daily for last 3 months was 278.46K.
What is the market cap of CRBP currently?
The market value of CRBP currently stands at $104.67M with its latest stock price at $8.35 and 12.54M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep